Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Oxacillin Sodium

FDA-approved product (capsule, oral), marketed as Bactocill, Bactocill In Plastic Container, Oxacillin Sodium and 1 more.

Registered studies
50+
Lab records
22
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Oxacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF04

Repurposing investigation

Oxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 9 of 22 lab records
Open Oxacillin Sodium in ChEMBL Registered studies below
Show the 22 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms

    NCT04037111 · start 2019-07-23

    Registered record
    Registry ID
    NCT04037111
    Conditions
    Major Depressive Disorder; Rheumatoid Arthritis
    Interventions
    Transcutaneous electrical vagus nerve stimulation; Sham vagus nerve stimulation; drug treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-07-23
    Completion
    2021-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Rheumatoid Arthritis
    InterventionTranscutaneous electrical vagus nerve stimulation; Sham vagus nerve stimulation; drug treatment
    PhaseNot applicable
    Registry statusUnknown

  • Ceftriaxone as Home IV for Staph Infections

    NCT04141787 · start 2019-07-11

    Registered record
    Registry ID
    NCT04141787
    Conditions
    Staphylococcal Infections; Osteomyelitis; CNS Infection; Septic Arthritis; Diabetic Foot Infection; Vertebral Osteomyelitis; Abscess; Coagulase Negative Staphylococcal Infection
    Interventions
    Ceftriaxone; Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-07-11
    Completion
    2024-03-30
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Infections; Osteomyelitis; CNS Infection; Septic Arthritis +4 more
    InterventionCeftriaxone; Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)
    PhasePhase 4
    Registry statusUnknown

  • Penicillin Against Flucloxacillin Treatment Evaluation

    NCT03632642 · start 2019-07-01

    Registered record
    Registry ID
    NCT03632642
    Conditions
    Staphylococcus Aureus
    Interventions
    Benzylpenicillin; Flucloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2019-07-01
    Completion
    2020-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus
    InterventionBenzylpenicillin; Flucloxacillin
    PhasePhase 4
    Registry statusWithdrawn

  • Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

    NCT03723551 · start 2019-02-20

    Registered record
    Registry ID
    NCT03723551
    Conditions
    Bone or Joint Infection
    Interventions
    Afabicin; Cefazolin; Vancomycin; Linezolid; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-02-20
    Completion
    2025-04-23
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone or Joint Infection
    InterventionAfabicin; Cefazolin; Vancomycin; Linezolid +1 more
    PhasePhase 2
    Registry statusTerminated

  • Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia

    NCT03108690 · start 2017-10-01

    Registered record
    Registry ID
    NCT03108690
    Conditions
    Bacteremia
    Interventions
    Continuous infusion of beta-lactam antibiotics .; Therapeutic drug monitoring of beta-lactam antibiotics.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-10-01
    Completion
    2023-03-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionContinuous infusion of beta-lactam antibiotics .; Therapeutic drug monitoring of beta-lactam antibiotics.
    PhasePhase 4
    Registry statusWithdrawn

  • Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients

    NCT02993575 · start 2017-06-01

    Registered record
    Registry ID
    NCT02993575
    Conditions
    Bacterial Infections
    Interventions
    Flucloxacillin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2018-04-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionFlucloxacillin
    PhaseNot recorded
    Registry statusCompleted

  • Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

    NCT02814916 · start 2017-03-30

    Registered record
    Registry ID
    NCT02814916
    Conditions
    Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    Interventions
    Dalbavancin; Vancomycin; Oxacillin; Flucloxacillin; Cefadroxil; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-30
    Completion
    2024-01-01
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    InterventionDalbavancin; Vancomycin; Oxacillin; Flucloxacillin +2 more
    PhasePhase 3
    Registry statusCompleted

  • Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)

    NCT03120663 · start 2016-11-30

    Registered record
    Registry ID
    NCT03120663
    Conditions
    Surgery
    Interventions
    amoxicillin-clavulanic acid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-11-30
    Completion
    2018-09-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgery
    Interventionamoxicillin-clavulanic acid
    PhaseNot recorded
    Registry statusUnknown

  • Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.

    NCT02983890 · start 2016-10-06

    Registered record
    Registry ID
    NCT02983890
    Conditions
    Healthy
    Interventions
    Dicloxacillin; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-10-06
    Completion
    2017-10-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDicloxacillin; Placebos
    PhasePhase 1
    Registry statusCompleted

  • Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

    NCT02344511 · start 2016-03

    Registered record
    Registry ID
    NCT02344511
    Conditions
    Osteomyelitis
    Interventions
    Dalbavancin; cefazolin, nafcillin, oxacillin or vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-03
    Completion
    2019-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    InterventionDalbavancin; cefazolin, nafcillin, oxacillin or vancomycin
    PhasePhase 3
    Registry statusWithdrawn

  • Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus

    NCT02701608 · start 2016-02-29

    Registered record
    Registry ID
    NCT02701608
    Conditions
    Infective Endocarditis
    Interventions
    Levofloxacin; Rifampicin; Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-29
    Completion
    2024-12-04
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfective Endocarditis
    InterventionLevofloxacin; Rifampicin; Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
    PhasePhase 3
    Registry statusCompleted

  • Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection

    NCT02365493 · start 2015-08-26

    Registered record
    Registry ID
    NCT02365493
    Conditions
    Methicillin-Resistant Staphylococcus Aureus
    Interventions
    Beta-Lactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-08-26
    Completion
    2018-10-24
    Enrolment
    358

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-Resistant Staphylococcus Aureus
    InterventionBeta-Lactam
    PhasePhase 3
    Registry statusTerminated

  • Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital

    NCT02334124 · start 2015-01

    Registered record
    Registry ID
    NCT02334124
    Conditions
    Cellulitis
    Interventions
    Home; Ward; ceftriaxone; flucloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01
    Completion
    2022-11
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCellulitis
    InterventionHome; Ward; ceftriaxone; flucloxacillin
    PhaseNot applicable
    Registry statusCompleted

  • A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

    NCT02208063 · start 2014-12

    Registered record
    Registry ID
    NCT02208063
    Conditions
    Bacteremia
    Interventions
    Telavancin; Vancomycin; Daptomycin; Synthetic penicillin; Cefazolin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-12
    Completion
    2018-04-12
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionTelavancin; Vancomycin; Daptomycin; Synthetic penicillin +1 more
    PhasePhase 3
    Registry statusTerminated

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated